Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia
JP Radich, E Olavarria… - Hematology/Oncology …, 2004 - hemonc.theclinics.com
There has never been a more difficult time to advise patients newly diagnosed with chronic
myeloid leukemia (CML). Until recently, the options comprised noncurative but relatively
nontoxic chemotherapy or potentially curative allogeneic stem cell transplantation, with its
attendant morbidity and mortality [1–3]. There now is the additional option of the tyrosine
kinase inhibitor imatinib mesylate (STI571, Gleevec, Glivec) that has been in clinical practice
for almost 5 years. Although data are emerging regarding the efficacy of imatinib, information …
myeloid leukemia (CML). Until recently, the options comprised noncurative but relatively
nontoxic chemotherapy or potentially curative allogeneic stem cell transplantation, with its
attendant morbidity and mortality [1–3]. There now is the additional option of the tyrosine
kinase inhibitor imatinib mesylate (STI571, Gleevec, Glivec) that has been in clinical practice
for almost 5 years. Although data are emerging regarding the efficacy of imatinib, information …